MA32898B1 - Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone - Google Patents
Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinoneInfo
- Publication number
- MA32898B1 MA32898B1 MA33939A MA33939A MA32898B1 MA 32898 B1 MA32898 B1 MA 32898B1 MA 33939 A MA33939 A MA 33939A MA 33939 A MA33939 A MA 33939A MA 32898 B1 MA32898 B1 MA 32898B1
- Authority
- MA
- Morocco
- Prior art keywords
- receptor
- arylmethylbenzoquinazolinone
- positive allosteric
- allosteric modulators
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/19—Acids containing three or more carbon atoms
- C07C53/21—Acids containing three or more carbon atoms containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La présente invention se rapporte à des composés de type benzoquinazolinone de formule (I) qui sont des modulateurs allostériques positifs du récepteur M1 et qui sont utiles pour le traitement de maladies dans lequel le récepteur M1 est mis en jeu, tel que la maladie d'Alzheimer, la schizophrénie, la douleur ou les troubles du sommeil. L'invention porte également sur des compositions pharmaceutiques comprenant les composés et sur l'utilisation des composés et des compositions pour le traitement de maladies médiées par le récepteur M1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19974008P | 2008-11-20 | 2008-11-20 | |
PCT/US2009/065060 WO2010059773A1 (fr) | 2008-11-20 | 2009-11-19 | Modulateurs allostériques positifs du récepteur m1 d’arylméthylbenzoquinazolinone |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32898B1 true MA32898B1 (fr) | 2011-12-01 |
Family
ID=41565956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33939A MA32898B1 (fr) | 2008-11-20 | 2011-06-13 | Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone |
Country Status (37)
Country | Link |
---|---|
US (4) | US8557832B2 (fr) |
EP (1) | EP2358686B1 (fr) |
JP (1) | JP5102397B2 (fr) |
KR (1) | KR101305590B1 (fr) |
CN (1) | CN102292323B (fr) |
BR (1) | BRPI0921924A2 (fr) |
CA (1) | CA2743562C (fr) |
CO (1) | CO6361928A2 (fr) |
CR (1) | CR20110268A (fr) |
CY (1) | CY1113665T1 (fr) |
DK (1) | DK2358686T3 (fr) |
DO (1) | DOP2011000135A (fr) |
EA (1) | EA019098B1 (fr) |
EC (1) | ECSP11011066A (fr) |
ES (1) | ES2393694T3 (fr) |
GE (1) | GEP20156348B (fr) |
GT (1) | GT201100127A (fr) |
HK (1) | HK1154587A1 (fr) |
HN (1) | HN2011001358A (fr) |
HR (1) | HRP20120992T1 (fr) |
IL (1) | IL212573A (fr) |
MA (1) | MA32898B1 (fr) |
MX (1) | MX2011005284A (fr) |
MY (1) | MY162502A (fr) |
NI (1) | NI201100100A (fr) |
NZ (1) | NZ592961A (fr) |
PE (1) | PE20120031A1 (fr) |
PL (1) | PL2358686T3 (fr) |
PT (1) | PT2358686E (fr) |
RS (1) | RS52528B (fr) |
SG (1) | SG171769A1 (fr) |
SI (1) | SI2358686T1 (fr) |
SV (1) | SV2011003912A (fr) |
TN (1) | TN2011000209A1 (fr) |
UA (1) | UA100459C2 (fr) |
WO (1) | WO2010059773A1 (fr) |
ZA (1) | ZA201103612B (fr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2473048T3 (pl) * | 2009-08-31 | 2015-08-31 | Merck Sharp & Dohme | Pozytywne modulatory allosteryczne receptora M1 piranyloarylometylobenzochinazolinonowe |
US8895580B2 (en) | 2009-10-21 | 2014-11-25 | Merck Sharp & Dohme Corp. | Quinolinone-pyrazolone M1 receptor positive allosteric modulators |
US8664387B2 (en) * | 2009-12-14 | 2014-03-04 | Merck Sharp & Dohme Corp. | Pyridoquinazolinone M1 receptor positive allosteric modulators |
MA33920B1 (fr) | 2009-12-17 | 2013-01-02 | Merck Sharp & Dohme | Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide |
WO2011084371A1 (fr) * | 2009-12-21 | 2011-07-14 | Merck Sharp & Dohme Corp. | Modulateurs allostériques positifs du récepteur m1 à base d'aminobenzoquinazolinone |
EP2582241B1 (fr) | 2010-06-15 | 2016-04-06 | Merck Sharp & Dohme Corp. | Compposés de phénanthrolinone fusionnés hétérocycliques utiles comme modulateurs allostériques positifs du récepteur m1 |
EP2588104B1 (fr) | 2010-07-01 | 2014-12-10 | Merck Sharp & Dohme Corp. | Modulateurs allostériques positifs du récepteur m1 de l'isoindolone |
WO2012047702A1 (fr) * | 2010-10-04 | 2012-04-12 | Merck Sharp & Dohme Corp. | Modulateurs allostériques positifs du récepteur m1 de dihydrobenzoquinazolinone |
WO2012158473A1 (fr) | 2011-05-17 | 2012-11-22 | Merck Sharp & Dohme Corp. | Modulateurs allostériques positifs du récepteur m1 au n-méthyl tétrahydro-quinoline |
EA201400215A1 (ru) | 2011-08-12 | 2014-07-30 | Басф Се | Антраниламидные соединения и их применение в качестве пестицидов |
IN2014CN00981A (fr) | 2011-08-12 | 2015-04-10 | Basf Se | |
WO2013097052A1 (fr) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Inhibiteurs de bromodomaine |
WO2013105117A1 (fr) * | 2012-01-10 | 2013-07-18 | Council Of Scientific & Industrial Research | Annulation médiée par cu pour la production de dérivés d'acide carboxylique d'1-amino-2-naphtalène |
JP6211509B2 (ja) | 2012-03-02 | 2017-10-11 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
JP6211530B2 (ja) | 2012-11-19 | 2017-10-11 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
JP6540690B2 (ja) * | 2014-04-17 | 2019-07-10 | 住友化学株式会社 | ニトロ化合物の製造方法 |
US20180050018A1 (en) * | 2015-03-06 | 2018-02-22 | Chase Pharmaceuticals Corporation | Peripheral-anticholinergic muscarinic agonist combination |
EA201890152A1 (ru) | 2015-06-26 | 2018-08-31 | Такеда Фармасьютикал Компани Лимитед | Производные 2,3-дигидро-4h-1,3-бензоксазин-4-онов в качестве модуляторов холинергического мускаринового m1 рецептора |
EP4019018A1 (fr) | 2015-09-11 | 2022-06-29 | Chase Pharmaceuticals Corporation | Combinaisons muscariniques et leur utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central |
EP3356332A4 (fr) | 2015-09-30 | 2019-06-19 | Merck Sharp & Dohme Corp. | Procédé de fabrication de modulateurs allostériques positifs du récepteur m1 |
EP3356333A4 (fr) * | 2015-09-30 | 2019-03-27 | Merck Sharp & Dohme Corp. | Formes cristallines d'un modulateur allostérique positif du récepteur m1 |
EP3366679B1 (fr) * | 2015-10-20 | 2021-03-24 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique |
DK3442972T3 (da) | 2016-04-15 | 2020-04-27 | Abbvie Inc | Bromdomænehæmmere |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
AU2017342205A1 (en) * | 2016-10-14 | 2019-04-04 | Pi Industries Ltd | 4-substituted phenylamine derivatives and their use to protect crops by fighting undesired phytopathogenic micoorganisms |
EP3535253A1 (fr) | 2016-11-01 | 2019-09-11 | H. Hoffnabb-La Roche Ag | 1,3-dihydro -1,4-benzodiazépine-2-thiones pour le traitement de maladies liées au snc |
US20200182850A1 (en) | 2017-05-19 | 2020-06-11 | Takeda Pharmaceutical Company Limited | Screening method |
US20210347786A1 (en) | 2018-09-28 | 2021-11-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US20240092783A1 (en) | 2021-03-18 | 2024-03-21 | Merck Patent Gmbh | Heteroaromatic compounds for organic electroluminescent devices |
WO2023114224A1 (fr) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combinaison de modulateurs positifs du récepteur muscarinique et de modulateurs allostériques positifs de nmda |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT856001E (pt) * | 1995-10-02 | 2003-01-31 | Hoffmann La Roche | Derivados de pirimidina enquanto antagonistas do receptor 5ht2c |
EP0946523A1 (fr) * | 1996-12-23 | 1999-10-06 | Celltech Therapeutics Limited | Derives polycyclique fondus de 2-aminopyrimidine, leur preparation et leur utilisation comme inhibiteurs de proteine tyrosine-kinase |
ES2244243T3 (es) * | 1998-10-16 | 2005-12-01 | Sumitomo Pharmaceuticals Company, Limited | Deerivados de quinazolinona. |
JP2005089298A (ja) * | 2001-09-18 | 2005-04-07 | Japan Tobacco Inc | ナフタレン化合物及びその医薬用途 |
US20060233843A1 (en) | 2003-02-19 | 2006-10-19 | Conn P J | Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
EP1888538B1 (fr) * | 2005-05-04 | 2009-11-18 | F. Hoffmann-Roche AG | (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amines exerçant une activite sur le recepteur 5-ht |
ATE530544T1 (de) * | 2006-06-28 | 2011-11-15 | Merck Sharp & Dohme | Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren |
WO2012047702A1 (fr) * | 2010-10-04 | 2012-04-12 | Merck Sharp & Dohme Corp. | Modulateurs allostériques positifs du récepteur m1 de dihydrobenzoquinazolinone |
-
2009
- 2009-11-19 ES ES09761104T patent/ES2393694T3/es active Active
- 2009-11-19 PE PE2011001058A patent/PE20120031A1/es not_active Application Discontinuation
- 2009-11-19 US US13/129,593 patent/US8557832B2/en active Active
- 2009-11-19 DK DK09761104.0T patent/DK2358686T3/da active
- 2009-11-19 NZ NZ592961A patent/NZ592961A/xx not_active IP Right Cessation
- 2009-11-19 UA UAA201107595A patent/UA100459C2/ru unknown
- 2009-11-19 MX MX2011005284A patent/MX2011005284A/es active IP Right Grant
- 2009-11-19 GE GEAP200912265A patent/GEP20156348B/en unknown
- 2009-11-19 WO PCT/US2009/065060 patent/WO2010059773A1/fr active Application Filing
- 2009-11-19 CA CA2743562A patent/CA2743562C/fr active Active
- 2009-11-19 PL PL09761104T patent/PL2358686T3/pl unknown
- 2009-11-19 PT PT97611040T patent/PT2358686E/pt unknown
- 2009-11-19 EP EP09761104A patent/EP2358686B1/fr active Active
- 2009-11-19 MY MYPI2011002215A patent/MY162502A/en unknown
- 2009-11-19 SG SG2011036472A patent/SG171769A1/en unknown
- 2009-11-19 CN CN200980155011.4A patent/CN102292323B/zh active Active
- 2009-11-19 JP JP2011537601A patent/JP5102397B2/ja active Active
- 2009-11-19 EA EA201170705A patent/EA019098B1/ru not_active IP Right Cessation
- 2009-11-19 KR KR1020117011415A patent/KR101305590B1/ko active IP Right Grant
- 2009-11-19 BR BRPI0921924A patent/BRPI0921924A2/pt active Search and Examination
- 2009-11-19 SI SI200930460T patent/SI2358686T1/sl unknown
- 2009-11-19 RS RS20120522A patent/RS52528B/en unknown
-
2011
- 2011-04-28 IL IL212573A patent/IL212573A/en not_active IP Right Cessation
- 2011-04-29 TN TN2011000209A patent/TN2011000209A1/fr unknown
- 2011-05-12 DO DO2011000135A patent/DOP2011000135A/es unknown
- 2011-05-17 ZA ZA2011/03612A patent/ZA201103612B/en unknown
- 2011-05-17 GT GT201100127A patent/GT201100127A/es unknown
- 2011-05-17 NI NI201100100A patent/NI201100100A/es unknown
- 2011-05-19 HN HN2011001358A patent/HN2011001358A/es unknown
- 2011-05-20 CR CR20110268A patent/CR20110268A/es unknown
- 2011-05-20 EC EC2011011066A patent/ECSP11011066A/es unknown
- 2011-05-20 SV SV2011003912A patent/SV2011003912A/es unknown
- 2011-05-24 CO CO11063884A patent/CO6361928A2/es active IP Right Grant
- 2011-06-13 MA MA33939A patent/MA32898B1/fr unknown
- 2011-08-25 HK HK11108976.8A patent/HK1154587A1/xx not_active IP Right Cessation
-
2012
- 2012-12-03 HR HRP20120992AT patent/HRP20120992T1/hr unknown
- 2012-12-17 CY CY20121101227T patent/CY1113665T1/el unknown
-
2013
- 2013-08-29 US US14/013,184 patent/US8883810B2/en active Active
-
2014
- 2014-10-08 US US14/509,580 patent/US20150031713A1/en not_active Abandoned
-
2015
- 2015-08-17 US US14/828,216 patent/US9708273B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32898B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone | |
TN2012000231A1 (en) | Quinoline amide m1 receptor positive allosteric modulators | |
EP2582676A4 (fr) | Modulateurs allostériques positifs du récepteur m1 de l'amide tétrahydroquinoline | |
ATE530544T1 (de) | Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren | |
MX2012002583A (es) | Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1. | |
ATE475650T1 (de) | Positive allosterische chinolon-m1- rezeptormodulatoren | |
ME00954B (fr) | Composés amino-hétérocycliques | |
UA113051C2 (xx) | Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів | |
UA99309C2 (ru) | Замещенные пиперидинодигидротиенопиримидины | |
EA201100062A1 (ru) | Соединения и способы модулирования рецепторов, связанных с белком g | |
EA201170624A1 (ru) | Изоникотинамидные антагонисты рецепторов орексинов | |
MY149855A (en) | Benzimidazole derivatives and their use for modulating the gaba? receptor complex | |
EA200971107A1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
MX367623B (es) | 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3. | |
EA200970065A1 (ru) | Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38 | |
BR112014001908A2 (pt) | derivados aza heterocíclicos substituídos | |
NZ605431A (en) | D2 antagonists, methods of synthesis and methods of use | |
ATE542795T1 (de) | Benzylpiperazinderivate als motilin- rezeptorantagonisten | |
MA32943B1 (fr) | Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique | |
MY183111A (en) | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators | |
ATE552257T1 (de) | Positive allosterische chinolizidinon-m1- rezeptormodulatoren | |
DE602007004327D1 (de) | Einen azepin-kern enthaltende antagonisten des histaminrezeptors | |
WO2009134668A3 (fr) | Modulateurs allostériques positifs pour le récepteur m1 de 4-oxo-1,4-dihydroquinoléine | |
WO2009117283A3 (fr) | Modulateurs allostériques positifs du récepteur m1 de la quinolizidine | |
ATE525370T1 (de) | Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten |